Market Place
Sourcing Support
Faron Pharmaceuticals Ltd: Holding(s) In Company
22 Apr 2026 //
PHARMIWEB
Faron Pharma Ltd: Holdings Overview
16 Apr 2026 //
PHARMIWEB
Faron Pharma Issues AGM Notice
10 Apr 2026 //
PHARMIWEB
Faron Pharmaceuticals Ltd: Director Dealing
19 Mar 2026 //
PHARMIWEB
Faron Pharma Ltd: Key Company Holdings
12 Mar 2026 //
ACCESSWIRE
Faron Pharma Adjusts 2026 Financial Calendar And AGM Date
09 Mar 2026 //
ACCESSWIRE
Faron Pharma Releases 2025 Annual Report
04 Mar 2026 //
PHARMIWEB
Faron Releases 2025 Financial Statements
04 Mar 2026 //
PHARMIWEB
Faron Pharma: Extraordinary General Meeting Notice
09 Feb 2026 //
PHARMIWEB
Faron Issues Second €10M Tranche of Convertible Bonds
11 Dec 2025 //
PHARMIWEB
Faron Pharma Ltd: Key Company Holdings
04 Dec 2025 //
PHARMIWEB
Faron Pharma Grants Stock Options
02 Dec 2025 //
ACCESSWIRE
Faron Pharmaceuticals Ltd: Appointment Of CFO
01 Dec 2025 //
PHARMIWEB
Faron to Issue Second €10M Convertible Bonds
24 Nov 2025 //
PHARMIWEB
Faron Pharmaceuticals Ltd: Holding(S) In Company
21 Oct 2025 //
ACCESSWIRE
Faron Pharma: Exercise of Option, Director Dealings, Equity Issue
19 Sep 2025 //
ACCESSWIRE
Faron Pharmaceuticals: Half-Year Financial Results Jan-Jun 2025
12 Sep 2025 //
ACCESSWIRE
Faron Pharmaceuticals Announces Half-Year Financial Results
19 Aug 2025 //
ACCESSWIRE
Faron Gets New US Patent for Bexmarilimab in Cancer Treatment
08 Aug 2025 //
ACCESSWIRE
Faron Pharmaceuticals Ltd: Company Holdings
08 Aug 2025 //
ACCESSWIRE
Faron to Present Updated Bexmab Data to Fda, Showing 43%
06 Aug 2025 //
ACCESSWIRE
Faron Study Highlights sClever-1 as Immune Blocker in Cancer
03 Jul 2025 //
INDPHARMAPOST
Faron Pharmaceuticals Ltd: Director Dealing
02 Jul 2025 //
ACCESSWIRE
Faron Pharmaceuticals Ltd: Director Donates Shares to Foundation
05 Jun 2025 //
PHARMAWEB
Faron Pharmaceuticals: Director Donates Shares to Foundation
05 Jun 2025 //
ACCESSWIRE
Faron Pharmaceuticals Ltd: Grant of Options
14 May 2025 //
ACCESSWIRE
Faron Pharmaceuticals Presents Promising BEXMAB Study Data at MDS
12 May 2025 //
ACCESSWIRE
Holding in Company
17 Apr 2025 //
ACCESSWIRE
Board Changes
21 Mar 2025 //
ACCESSWIRE
Faron presents Bexmab data at ASH Annual Meeting
10 Dec 2024 //
PR NEWSWIRE
Faron Confirms Plans for the Coming Months Under New Leadership
16 Apr 2024 //
GLOBENEWSWIRE
Inside Information: Additional Positive Data from the Ph1 Part of BEXMAB Study
18 Mar 2024 //
GLOBENEWSWIRE
Positive Data from the Ph1 Part of the BEXMAB Study Failed
18 Mar 2024 //
GLOBENEWSWIRE
Faron™s Financial Statement Release January 1 to December 31, 2023
13 Mar 2024 //
GLOBENEWSWIRE
Detailed Analysis of BEXMAB Data Provides Insights into Patient Profiles of Responding HMA-Failed MDS Population
25 Jan 2024 //
GLOBENEWSWIRE
Faron Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Jan 2024 //
GLOBENEWSWIRE
Faron Presents Phase 1 Data from BEXMAB in Myeloid Malignancies Trial
11 Dec 2023 //
GLOBENEWSWIRE
Announcement of the Results of Placing, the Issue Price with the Trade Register
27 Oct 2023 //
GLOBENEWSWIRE
Faron Announces Positive BEXMAB Study Update in Relapsed/Refractory AML
11 Oct 2023 //
GLOBENEWSWIRE
Faron Pharmaceuticals Announces Board Changes
22 Sep 2023 //
GLOBENEWSWIRE
Faron Appoints Dr. Birge Berns, MD as Interim Chief Medical Officer
21 Sep 2023 //
GLOBENEWSWIRE
Faron to Present at the H.C. Wainwright 25th Annual Global Investment Conference
06 Sep 2023 //
GLOBENEWSWIRE
Faron Reports Half-Year Financial Results, January 1 June 30, 2023
29 Aug 2023 //
GLOBENEWSWIRE
Faron Pharmaceuticals Notice of Half-Year Financial Results
04 Aug 2023 //
GLOBENEWSWIRE
Faron to Participate in Fireside Chat at the Canaccord Genuity Annual Conference
02 Aug 2023 //
GLOBENEWSWIRE
Faron to Hold Conference to Discuss Data from Phase I/II Study of Bexmarilimab
19 Jul 2023 //
GLOBENEWSWIRE
Faron`s latest snapshot suggests antibody has leukemia potential
19 Jul 2023 //
FIERCE BIOTECH
Faron Appoints Maija Hollmén as CSO
01 Dec 2022 //
CISION
Faron Names Dr. Maija Hollmén as Chief Scientific Officer
01 Dec 2022 //
CONTRACTPHARMA
Faron Pharmaceuticals hails potential of cancer immunotherapy
19 Sep 2022 //
PROACTIVEINVESTORS
Presentation of Biomarker Analysis at ASCO
30 May 2022 //
PRNEWSWIRE
Faron Announces FDA and FMA Approval to Initiate PI/II Bexmarilimab
16 May 2022 //
PRNEWSWIRE
Faron Presents Results from Melanoma Cohort of MATINS Trial at 18th Congress
21 Apr 2022 //
PRNEWSWIRE
Financial Statement January 1 to December 31 2021
24 Mar 2022 //
PRNEWSWIRE
UK Health Secretary: rise in COVID-19 cases ‘expected’
14 Mar 2022 //
PHARMAFILE
Presentation of Biomarker Data at AACR
09 Mar 2022 //
PRNEWSWIRE
Faron Updates on Bexmarilimab Development Program
22 Feb 2022 //
PRNEWSWIRE
Faron Announces R&D Day
14 Feb 2022 //
PRNEWSWIRE
Faron announces new COO to catapult cancer immunotherapy development
31 Jan 2022 //
PROACTIVEINVESTORS
Faron Announces Topline MATINS Biomarker Analysis
09 Dec 2021 //
PRNEWSWIRE
